Improvement of pyoderma gangrenosum and psoriasis associated with crohn disease with anti-tumor necrosis factor α monoclonal antibody

Mei Heng Tan, Marsha Gordon, Oscar Lebwohl, James George, Mark G. Lebwohl

Research output: Contribution to journalArticlepeer-review

162 Scopus citations

Abstract

Background: Infliximab is an anti-tumor necrosis factor α monoclonal antibody IgG effective in the treatment and maintenance of remission of active refractory Crohn disease and associated draining enterocutaneous fistulae. Multiple infusions of infliximab show promising results in patients with rheumatoid arthritis. Currently, there is limited clinical experience with infliximab, and no published reports exist on its use in cutaneous disorders. Observations: We describe 2 patients with Crohn disease and pyoderma gangrenosum and 1 patient with Crohn disease and psoriasis who were treated with infliximab for recalcitrant Crohn fistulae, with concurrent improvement in their skin diseases. Conclusions: These cases suggest that infliximab, a promising therapeutic agent for refractory Crohn disease and fistulae, may also be effective in the treatment of pyoderma gangrenosum and psoriasis associated with Crohn disease.

Original languageEnglish
Pages (from-to)930-933
Number of pages4
JournalArchives of Dermatology
Volume137
Issue number7
StatePublished - 2001
Externally publishedYes

Fingerprint

Dive into the research topics of 'Improvement of pyoderma gangrenosum and psoriasis associated with crohn disease with anti-tumor necrosis factor α monoclonal antibody'. Together they form a unique fingerprint.

Cite this